Mostrar registro simples

dc.contributor.authorTemes, Bárbara Alemar Beserrapt_BR
dc.contributor.authorSilva, Cleandra Gregóriopt_BR
dc.contributor.authorHerzog, Josefpt_BR
dc.contributor.authorBittar, Camila Matzenbacherpt_BR
dc.contributor.authorNetto, Cristina Brinckmann Oliveirapt_BR
dc.contributor.authorArtigalas, Osvaldo Alfonso Pintopt_BR
dc.contributor.authorSchwartz, Ida Vanessa Doederleinpt_BR
dc.contributor.authorCoffa, Jordypt_BR
dc.contributor.authorCamey, Suzi Alvespt_BR
dc.contributor.authorWeitzel, Jeffreypt_BR
dc.contributor.authorProlla, Patrícia Ashtonpt_BR
dc.date.accessioned2018-02-16T02:29:48Zpt_BR
dc.date.issued2017pt_BR
dc.identifier.issn1932-6203pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/172590pt_BR
dc.description.abstractBackground Germline pathogenic variants in BRCA1 and BRCA2 (BRCA) are the main cause of Hereditary Breast and Ovarian Cancer syndrome (HBOC). Methods In this study we evaluated the mutational profile and prevalence of BRCA pathogenic/likely pathogenic variants among probands fulfilling the NCCN HBOC testing criteria. We characterized the clinical profile of these individuals and explored the performance of international testing criteria. Results A pathogenic/likely pathogenic variant was detected in 19.1% of 418 probands, including seven novel frameshift variants. Variants of uncertain significance were found in 5.7% of individuals. We evaluated 50 testing criteria and mutation probability algorithms. There was a significant odds-ratio (OR) for mutation prediction (p 0.05) for 25 criteria; 14 of these had p 0.001. Using a cutoff point of four criteria, the sensitivity is 83.8%, and the specificity is 53.5% for being a carrier. The prevalence of pathogenic/likely pathogenic variants for each criterion ranged from 22.1% to 55.6%, and criteria with the highest ORs were those related to triple-negative breast cancer or ovarian cancer. Conclusions This is the largest study of comprehensive BRCA testing among Brazilians to date, and the first to analyze clinical criteria for genetic testing. Several criteria that are not included in the NCCN achieved a higher predictive value. Identification of the most informative criteria for each population will assist in the development of a rational approach to genetic testing, and will enable the prioritization of high-risk individuals as a first step towards offering testing in low-income countries.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofPLoS ONE. San Francisco. Vol. 12, no. 11 (Nov. 2017), p. e0187630, 18 p.pt_BR
dc.rightsOpen Accessen
dc.subjectEstatística médicapt_BR
dc.subjectNeoplasias ovarianaspt_BR
dc.subjectPrevalênciapt_BR
dc.titleBRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil : are international testing criteria appropriate for this specific population?pt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001055204pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples